The top 5 OncLive TV videos of the week cover pancreatic cancer, gastric cancer, GIST, renal cell carcinoma, and chronic lymphocytic leukemia.
Commentary|Articles|February 19, 2025
Experts Break Down Practice-Informing Presentations From the 2025 Genitourinary Cancers Symposium
Author(s)Courtney Flaherty
Fact checked by: Ashling Wahner
Experts across the field of GU oncology share important insights and spotlight key research presented at the 2025 GU Cancers Symposium.
Advertisement
Advertisement
The
Related to this article
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Huntsman Cancer Institute at the University of Utah celebrated a major milestone in the development of Huntsman Cancer Institute in Vineyard.
Advertisement
Advertisement